Xenoport Inc (XNPT.O) People | Reuters.com
Edition:
United States

Xenoport Inc (XNPT.O)

XNPT.O on Nasdaq

7.02USD
29 Jun 2016
Change (% chg)

-- (+0.00%)
Prev Close
$7.02
Open
$7.03
Day's High
$7.04
Day's Low
$7.01
Volume
371,660
Avg. Vol
1,310,638
52-wk High
$7.86
52-wk Low
$3.35

Summary

Name Age Since Current Position

John Freund

61 2015 Chairman of the Board

Vincent Angotti

48 2015 Chief Executive Officer, Director

William Harris

57 2011 Chief Financial Officer, Senior Vice President - Finance

Gregory Bates

57 2012 Senior Vice President - Regulatory Affairs and Quality

Richard Kim

45 2014 Senior Vice President - Clinical Development and Medical Affairs, Chief Medical Officer

William Rieflin

56 2010 Director

Dennis Fenton

64 2009 Independent Director

Catherine Friedman

55 2007 Independent Director

Jeryl Hilleman

57 2005 Independent Director

Wendell Wierenga

67 2000 Independent Director

Biographies

Name Description

John Freund

Dr. John G. Freund, M.D., is Chairman of the Board of XenoPort, Inc., effective as of September 29, 2015. He has been a member of our board of directors since 1999 and our lead independent director since July 2008. He has been a managing director of Skyline Ventures, a venture capital firm specializing in healthcare companies, since 1997. From 1995 to 1997, Dr. Freund was a managing director in the private equity group at Chancellor Capital Management, a private capital investment firm. AMVESCAP plc, an investment services company, acquired Chancellor Capital Management in 1998 and renamed the division INVESCO Private Capital. In 1995, he co-founded Intuitive Surgical, Inc., a medical device company. From 1988 to 1994, he held various positions at Acuson Corp., a maker of ultrasound equipment, most recently as executive vice president. Siemens Corp. acquired Acuson in 2000. Prior to Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners, a venture capital management firm, from 1987 to 1988. From 1982 to 1988, Dr. Freund was at Morgan Stanley & Co., an investment banking company, where he was a co-founder of the Healthcare Group in the Corporate Finance Department. He received a B.A. from Harvard College, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School.

Vincent Angotti

Mr. Vincent J. Angotti is Chief Operating Officer, Executive Vice President of XenoPort, Inc., effective September 29, 2015. He was previously our executive vice president and chief operating officer from June 2012 to October 2015. Prior to that, Mr. Angotti was our senior vice president and chief commercialization officer from May 2008 to June 2012. From 2001 to 2008, he held several positions with Reliant Pharmaceuticals, Inc., the most recent of which was senior vice president of sales and marketing. GlaxoSmithKline acquired Reliant Pharmaceuticals in 2008. Prior to Reliant Pharmaceuticals, from 1991 to 2001, Mr. Angotti held several positions at Novartis Pharmaceuticals Corporation, most recently as executive director, field operations. Mr. Angotti received a B.S. from Cornell University and an M.B.A. from Columbia University.

William Harris

Mr. William G. Harris is Chief Financial Officer, Senior Vice President - Finance of XenoPort Inc., since November 2001. From 1996 to 2001, From 1996 to 2001, he held several positions with Coulter Pharmaceutical, Inc., a biotechnology company engaged in the development of novel therapies for the treatment of cancer and autoimmune diseases, the most recent of which was senior vice president and chief financial officer. Corixa Corp., a developer of immunotherapeutic products, acquired Coulter Pharmaceutical in 2000. Prior to Coulter Pharmaceutical, from 1990 to 1996, Mr. Harris held several positions at Gilead Sciences, Inc., the most recent of which was director of finance. Mr. Harris received a B.A. from the University of California, San Diego and an M.B.A. from Santa Clara University, Leavey School of Business and Administration. Mr. Harris is a member of the board of directors of Capnia, Inc., a publicly-traded commercial stage medical diagnostics and therapeutics company.

Gregory Bates

Mr. Gregory T. Bates, D.V.M., is Senior Vice President - Regulatory Affairs and Quality of XenoPort, Inc. since June 2012. He was previously our vice president of regulatory affairs from 2006 to June 2012. From 1998 to 2006, Dr. Bates held various positions at Pharmacyclics, Inc, a biopharmaceutical company, the most recent of which was senior director of regulatory affairs. Prior to Pharmacyclics, in 1998, Dr. Bates was director of regulatory affairs and quality at Otsuka America Pharmaceutical, Inc. From 1995 to 1998, he was manager of regulatory affairs at Genentech, Inc., a biotechnology company, and from 1990 to 1995, he was senior manager of agribusiness regulatory affairs at Syntex (USA), Inc., a pharmaceutical company. Dr. Bates received a B.A. from the University of California, Berkeley and a Doctor of Veterinary Medicine from the University of California, Davis.

Richard Kim

Dr. Richard Kim, M.D. is the Senior Vice President - Clinical Development , Medical Affairs, and Chief Medical Officer of XenoPort, Inc. He was previously our vice president of medical affairs from July 2013 to January 2014. From 2012 to 2013, Dr. Kim was vice president of clinical development and head of the multiple sclerosis therapeutic area, and from 2010 to 2012, he was senior director, clinical development at Elan Pharmaceuticals, Inc. Prior to that, from 2006 to 2010, Dr. Kim was global medical director, medical affairs at Biogen Idec Inc. From 2004 to 2006, he was medical director, clinical development for EMD Serono, Inc. Prior to that, he was associate medical director from 2002 to 2004 at Purdue Pharma L.P. Dr. Kim received a B.S. degree from University of California at Los Angeles and his M.D. from Tulane University. He completed his neurology residency training at Stanford University, and is currently a diplomat of the American Board of Psychiatry and Neurology.

William Rieflin

Mr. William J. Rieflin is Director of XenoPort, Inc., since September 2010. In September 2010, Mr. Rieflin has been a member of our board of directors since September 2010. In September 2010, Mr. Rieflin was appointed chief executive officer and a member of the board of directors of NGM Biopharmaceuticals, Inc., a privately held biopharmaceutical company focused on metabolic diseases. Mr. Rieflin previously served as our president from 2004 to September 2010. From 1996 to 2004, he held various positions with Tularik Inc., a biotechnology company focused on the discovery and development of product candidates based on the regulation of gene expression, most recently as executive vice president, administration, chief financial officer, general counsel and secretary. Amgen Inc. acquired Tularik in 2004. Mr. Rieflin received a B.S. from Cornell University, an M.B.A. from the University of Chicago Graduate School of Business and a J.D. from Stanford Law School.

Dennis Fenton

Dr. Dennis M. Fenton, Ph.D., is Independent Director of XenoPort, Inc., since August 2009. From 1982 to 2008, Dr. Fenton has been a member of our board of directors since August 2009. From 1982 to 2008, Dr. Fenton held numerous positions, including executive roles in process development, manufacturing, sales and marketing and research and development, at Amgen, Inc., a biotechnology company. From 2000 to 2008, Dr. Fenton was executive vice president responsible for worldwide operations, manufacturing, process development and quality. From 1995 to 2000, Dr. Fenton was senior vice president of operations, and from 1992 to 1995, Dr. Fenton was senior vice president of sales, marketing and process development for Amgen. Dr. Fenton received a B.S. in biology from Manhattan College and a Ph.D. in microbiology from Rutgers University.

Catherine Friedman

Ms. Catherine J. Friedman is Independent Director of XenoPort, Inc., since September 2007. Ms. Friedman has been a member of our board of directors since September 2007. Ms. Friedman has been an independent financial consultant to private and public companies in the life sciences industry since 2006. Prior to that, Ms. Friedman held numerous positions over a 23-year investment banking career with Morgan Stanley & Co., an investment banking company, including Managing Director from 1997 to 2006 and Head of West Coast Healthcare and Co-Head of the Biotechnology Practice from 1993 to 2006. Ms. Friedman received a B.A. from Harvard College and an M.B.A. from the University of Virginia Darden School of Business.

Jeryl Hilleman

Ms. Jeryl L. Hilleman is Independent Director of XenoPort, Inc., since January 2005. From January 2008 to May 2012, she has been a member of our board of directors since January 2005. She has served as the chief financial officer at Intersect ENT, Inc., a medical device company, since June 2014. Prior to joining Intersect ENT in June 2014, she served as the chief financial officer, chief accounting officer and secretary of the biopharmaceutical company Ocera Therapeutics, Inc., a biopharmaceutical company. Prior to joining Ocera in September 2013, Ms. Hilleman provided independent financial and strategic consulting for biotech and cleantech companies. From January 2008 to May 2012, she was chief financial officer of Amyris Biotechnologies, Inc., a company specializing in synthetic biology. Prior to joining Amyris in January 2008, she was executive vice president and chief financial officer of Symyx Technologies, Inc., a company specializing in high-throughput experimentation for the discovery of materials, from 1997 to June 2007. Prior to joining Symyx in 1997, Ms. Hilleman served as vice president finance and chief financial officer of two public biotechnology companies, Geron Corporation and Cytel Corporation, which merged with Epimmune Inc. in 1999. Ms. Hilleman received an A.B. from Brown University and an M.B.A. from the Wharton Graduate School of Business.

Wendell Wierenga

Dr. Wendell Wierenga, Ph.D., is Independent Director of XenoPort, Inc., since 2000. He has been a member of our board of directors since 2000. From June 2011 to February 2014, he served as executive vice president, research and development at Santarus, Inc., a publicly-traded specialty biopharmaceutical company that was acquired by Salix Pharmaceuticals, Ltd. in January 2014. Prior to joining Santarus, Dr. Wierenga was executive vice president of research and development at Ambit Biosciences, Inc., a biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors, from January 2007 to May 2011. Dr. Wierenga was executive vice president of research and development at Neurocrine Biosciences, Inc., a biopharmaceutical company developing therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases, from 2003 to 2007. From 2000 to 2003, Dr. Wierenga was chief executive officer of Syrrx, Inc., a company focused on small-molecule drug compounds. Prior to joining Syrrx, from 1990 to 2000, he was senior vice president of worldwide pharmaceutical sciences, technologies and development at Parke-Davis, a division of Warner Lambert Co., a pharmaceutical company. Pfizer Inc., a research-based pharmaceutical company, acquired Warner Lambert in 2000. Prior to Parke-Davis, Dr. Wierenga worked at Upjohn Co., later Pharmacia & Upjohn, Inc., a pharmaceutical and biotechnology company, for 16 years in various positions, most recently as executive director of discovery research. Pfizer acquired Pharmacia & Upjohn, then named Pharmacia Corp., in 2002. Dr. Wierenga is currently a member of the board of directors of Cytokinetics, Inc., Ocera Therapeutics, Concert Pharmaceuticals, Inc., Apricus Biosciences, Inc. and Anacor Pharmaceuticals, Inc., all of which are publicly-traded biopharmaceutical companies. Dr. Wierenga received a B.S. from Hope College and a Ph.D. in chemistry from Stanford University.

Basic Compensation

Options Compensation